1-10 of 10
Lyndah K. Dreiling
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Jennifer R. Brown, MD PhD, Andrew D. Zelenetz, MD PhD, Richard R. Furman, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Marco Montillo, MD, Susan M. O'Brien, MD, Lyndah K. Dreiling, MD, Ronald L. Dubowy, MD, Yeonhee Kim, PhD, Veerendra B. Munugalavada, PhD, Tadeusz Robak, MD PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3016.
https://doi.org/10.1182/blood.V130.Suppl_1.3016.3016
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Genome-Wide Association Study of the Human Genetic Factors Influencing the Risk of Adverse Events during Idelalislib Therapy in Patients with Relapsed Indolent Lymphoma

Patrick R. Shea, David B. Goldstein, Veerendra Munugalavadla, Lyndah K. Dreiling, Sarah E. Kleinstein, Wojciech Jurczak, Ian W. Flinn, MD PhD, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 5284.
https://doi.org/10.1182/blood.V128.22.5284.5284
Published: 2016
Journal Articles

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Jeffrey P. Sharman, Gilles A. Salles, Wojciech Jurczak, Jeffrey Jones, Carolyn J. Owen, MD MDes(UK), FRCPC, Veerendra Munugalavadla, Lyndah K. Dreiling, Yuanyuan Xiao, Arati V. Rao, Ian W. Flinn, MD PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 5583.
https://doi.org/10.1182/blood.V128.22.5583.5583
Published: 2016
Journal Articles

Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis

Richard R. Furman, Michael Hallek, Jeffrey P. Sharman, Peter Hillmen, Andrew D. Zelenetz, Ian W. Flinn, MD PhD, Wojciech Jurczak, Veerendra Munugalavadla, Yuanyuan Xiao, Lianqing Zheng, Arati V. Rao, Lyndah K. Dreiling, Gilles A. Salles, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 5588.
https://doi.org/10.1182/blood.V128.22.5588.5588
Published: 2016
Journal Articles

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Paolo Ghia, Viktor Ljungström, Eugen Tausch, Andreas Agathangelidis, Annika Scheffold, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Carolyn J. Owen, MD MDes(UK), FRCPC, Jacqueline C. Barrientos, MD, Marc Zapatka, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Yeonhee Kim, Ronald L. Dubowy, Lyndah K. Dreiling, Richard Rosenquist, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 2770.
https://doi.org/10.1182/blood.V128.22.2770.2770
Published: 2016
Journal Articles

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Clinical Trials & Observations Brief Report
Paul M. Barr, Gene B. Saylors, Stephen E. Spurgeon, Bruce D. Cheson, Daniel R. Greenwald, Susan M. O’Brien, Andre K. D. Liem, Rosemary E. Mclntyre, Adarsh Joshi, Esteban Abella-Dominicis, Michael J. Hawkins, Anita Reddy, Julie Di Paolo, Hank Lee, Joyce He, Jing Hu, Lyndah K. Dreiling, Jonathan W. Friedberg
Journal: Blood
Blood (2016) 127 (20): 2411–2415.
https://doi.org/10.1182/blood-2015-12-683516
Published: 2016
Includes: Supplemental data
Journal Articles

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Andrew D Zelenetz, MD, PhD, Tadeusz Robak, MD, PhD, Bertrand Coiffier, MD, PhD, Julio Delgado, MD, Paula Marlton, MBBS, Adeboye H Adewoye, MD, Yeonhee Kim, PhD, Lyndah K. Dreiling, MD, Peter Hillmen, MB, ChB, PhD
Journal: Blood
Blood (2015) 126 (23): LBA-5.
https://doi.org/10.1182/blood.V126.23.LBA-5.LBA-5
Published: 2015
Journal Articles

Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.

Thomas C. Shea, MD, Tarun Kewalramani, MD, Yong Mun, Gerald Jayne, Lyndah K. Dreiling, MD
Journal: Blood
Blood (2006) 108 (11): 3073.
https://doi.org/10.1182/blood.V108.11.3073.3073
Published: 2006